Key facts
- This page summarizes David R. Ebsworth's Form 4 filing for Verona Pharma plc (VRNA).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 28 Feb 2025, 16:30.
David R. Ebsworth - 26 Feb 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)
- Reporting relationship
- Director
- Issuer ticker
- VRNA
- Reported as of
- 26 Feb 2025
- Net transaction value
- +$600,060
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2025, 16:30:14 UTC
- Prior SEC filing
- 18 Nov 2024
- Next SEC filing
- 29 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Fisher, Attorney-in-fact for David R. Ebsworth
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David R. Ebsworth filed Form 4 for Verona Pharma plc (VRNA) on 28 Feb 2025.
Change
- Previous filing in this sequence was filed on 18 Nov 2024.
- Current net transaction value: +$600,060.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRNA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $49,600
- Shares
- +64,000
- Change %
- +6.8%
- Price
- $0.7750
- Shares after
- 1,004,003
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
VRNA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $100,760
- Shares
- +200,000
- Change %
- +20%
- Price
- $0.5038
- Shares after
- 1,204,003
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
VRNA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $256,320
- Shares
- +96,000
- Change %
- +8%
- Price
- $2.67
- Shares after
- 1,300,003
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
VRNA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $193,380
- Shares
- +100,000
- Change %
- +7.7%
- Price
- $1.93
- Shares after
- 1,400,003
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
VRNA
transaction
Ordinary Shares
Gift
- Transaction value
- $0
- Shares
- -64,000
- Change %
- -4.6%
- Price
- $0.000000
- Shares after
- 1,336,003
- Date
- 26 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRNA
transaction
Derivative
Share Option (Right to Exercise)
Options Exercise
- Transaction value
- $0
- Shares
- -64,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 64,000
- Exercise price
- $0.7750
- Footnotes
- F3, F4
VRNA
transaction
Derivative
Share Option (Right to Exercise)
Options Exercise
- Transaction value
- $0
- Shares
- -200,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 200,000
- Exercise price
- $0.5038
- Footnotes
- F3, F4
VRNA
transaction
Derivative
Share Option (Right to Exercise)
Options Exercise
- Transaction value
- $0
- Shares
- -96,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 96,000
- Exercise price
- $2.67
- Footnotes
- F3, F4
VRNA
transaction
Derivative
Share Option (Right to Exercise)
Options Exercise
- Transaction value
- $0
- Shares
- -100,000
- Change %
- -42%
- Price
- $0.000000
- Shares after
- 140,000
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 100,000
- Exercise price
- $1.93
- Footnotes
- F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Footnote F2
Consists of (i) 1,336,000 Ordinary Shares represented by 167,000 ADSs and (ii) 3 Ordinary Shares.
Footnote F3
The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Footnote F4
The option is fully vested.
Footnote F5
The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025.